Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,206 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06478394Recruiting
Blood test for hidden stomach cancer spread
This study tests a new blood test that uses machine learning to find hidden stomach cancer spread (peritoneal metastases) early. It could help people with locally advanced stomach cancer avoid unnecessary surgery.
Shijiazhuang, HebeiAges 18 years+ - NCT06890221Recruiting
Nutrition therapy before and after breast cancer surgery
This trial tests if a special nutrition drink before and after mastectomy can help breast cancer patients recover better. It uses a body measurement called bioimpedance phase angle to see how nutrition affects your cells and healing.
Petaling Jaya, Kuala LumpurAges 18 years+ - NCT06679387RecruitingPhase 2
Memantine to prevent paclitaxel nerve damage in breast cancer
This trial tests whether the drug memantine can help prevent or reduce nerve pain and other side effects caused by the chemotherapy drug paclitaxel in breast cancer patients. If you are about to start weekly paclitaxel, this study may offer extra protection to your nerves.
CairoAges 18 years+ - NCT06518837RecruitingPhase 2
Tirzepatide for weight loss in early breast cancer
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Elizabeth, New JerseyAges 18 years+ - NCT07135960Recruiting
Breast motion study after surgery and radiation
This study uses a 3D scanner to measure how your breast moves after surgery and possibly radiation. The results may help doctors improve treatment planning for future patients.
PortsmouthAges 18 years+ - NCT07661927RecruitingPhase 2
Skipping hormone therapy for low-risk breast cancer
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
AngersAges 60 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT07702708Recruiting
AI predicts chemotherapy response in HR+/HER2- breast cancer
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Fuzhou, FujianAges 18 years+ - NCT04690439Recruiting
Light therapy to treat breast cancer–related arm swelling
This trial studies whether a noninvasive light-based treatment (photobiomodulation) can reduce breast cancer–related lymphedema, which is swelling in the arm or chest area due to lymph fluid buildup. If you qualify, you’ll be asked to follow a set treatment and follow-up schedule to see if symptoms improve safely.
Hasselt, LimburgAges 18 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT05320588RecruitingPhase 1/Phase 2
Early test of a cancer treatment for advanced solid tumors
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
Austin, TexasAges 18 years+ - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05466786Recruiting
Testing gene changes and DNA damage in HER2-low breast cancer
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Guangzhou, GuangdongAges 18–70 - NCT05475678RecruitingPhase 2
Camrelizumab plus chemo before surgery for triple-negative breast cancer
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
Zhengzhou, HenanAges 18–70 - NCT05608252RecruitingPhase 1/Phase 2
Drug combination for advanced ER-positive, HER2-negative breast cancer
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Boston, MassachusettsAges 18 years+ - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05972343Recruiting
Cooling treatment to shrink breast tumors without surgery
This trial tests a cooling-based procedure (called cryoablation) to destroy a breast cancer tumor in people who cannot or do not want surgery. It may help shrink the visible tumor without needing an operating room.
St Louis, MissouriAges 18 years+ - NCT06127797Recruiting
MRI surveillance study for breast cancer survivors with dense breasts
This study is testing whether adding an MRI to your regular mammogram can help find any new breast cancers earlier. It is for women who have had breast cancer before and still have dense breast tissue, making mammograms harder to read.
Houston, TexasAges 18 years+ - NCT06150898RecruitingPhase 2
Ketorolac and pregabalin for estrogen receptor positive breast cancer before surgery
This trial tests whether two medications, ketorolac (a pain reliever) and pregabalin (a nerve pain drug), can help treat estrogen receptor (ER) positive breast cancer when taken before surgery. It may offer better pain control and possibly improve cancer outcomes.
Brussels, Brussels CapitalAges 18–70 - NCT06182306Recruiting
Testing a tool to guide treatment for triple-negative breast cancer
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
LondonAges 18 years+ - NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,206 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.